MedPacto, Inc. (KOSDAQ:235980)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,120.00
-220.00 (-3.47%)
Jan 19, 2026, 3:30 PM KST
45.71%
Market Cap209.76B
Revenue (ttm)2.47B
Net Income (ttm)-14.57B
Shares Out34.28M
EPS (ttm)-426.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume351,599
Average Volume311,946
Open6,400.00
Previous Close6,340.00
Day's Range6,020.00 - 6,400.00
52-Week Range2,750.00 - 8,650.00
Beta0.49
RSI40.77
Earnings DateMar 19, 2026

About MedPacto

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Seong-Jin Kim
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 235980
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.